Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology ...
For all of the benefit that radiopharmaceuticals offer, these treatments currently address a limited number of cancer targets. Aktis Oncology ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. ...
WASHINGTON — Health secretary Robert F. Kennedy Jr. and many top deputies are scheduled to speak alongside industry executives and ...
Bidding to buy metabolic medicines biotech Metsera in September came down to two pharmaceutical giants, with Novo Nordisk’s higher offer ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and ...
Prime Medicine, a biotech whose wild ambitions for a powerful gene editing technology sank as the biotech market slumped, announced Monday ...
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you ...
Caribou Biosciences’ 2025 outlook aimed for key trial readouts for two cancer cell therapies in the first half of the ...
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the ...
MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to ...
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.
Copyright © 2025 Your Health 24 7.
Your Health 24 7 is not responsible for the content of external sites.